Researchers behind a study at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting 3q26.2’s destructive nature. …
A report of their findings was published online in the journal Proceedings of the National Academy of Sciences on Dec. 1. Triple-negative breast cancers account for about 20 percent of all breast cancers in the United States, and 30 percent of all breast cancers in African-American women. …
The study suggests that attacking those subsets with targeted drugs may degrade the disease’s ability to spread throughout the bone marrow of affected patients, the authors say. The discovery was made by developing a mouse model of the disease that enabled researchers to track which of 15 genetic groups — or subclones — of myeloma cells spread beyond their initial site in the animals’ hind legs. By labeling the different subgroups with fluorescent dyes, researchers determined that just one of the subclones was responsible for the disease metastasis. They then compared the pattern of gene abnormalities in the initial myeloma tissue and the metastatic tumors. …
A report of their findings was published online in the journal Proceedings of the National Academy of Sciences on Dec. 1. Triple-negative breast cancers account for about 20 percent of all breast cancers in the United States, and 30 percent of all breast cancers in African-American women…
Researchers behind a study at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting 3q26.2’s destructive nature. By manipulating a non-coding microRNA (miRNA) known as miR569 that is part of the amplicon, scientists were able to increase cell death in vitro and in vivo…
Their findings will be reported online Dec. 6 in the New England Journal of Medicine, and presented on Dec. …
The results provide some of the most dramatic evidence to date of the potential of therapies that increase the ability of the immune system to kill cancer cells. While clinical trials of such immunotherapies in other cancers have shown them to be highly effective in a subgroup of patients, the new study stands out because nearly all patients benefited from the treatment…
The team identified a critical pathway of molecular signals which throw a lifeline to cancer cells, enabling them to survive even though they contain vast DNA errors which would usually trigger cell death. The PKCƐ signal pathway, which is used by cancer cells but rarely by normal cells, could be important in targeting some cancer cells as they rely on this pathway to survive…
The question becomes who is invading whom — do cancer cells invade the basement membrane or do some fibroblasts help invading cancers? Researchers at the Institut Curie in Paris now say that they have evidence of a coordinated attack on the basement membrane by cancer cells in situ and CAF cells in the extracellular matrix that begins long before the actual translocation of cancer cells. …
The findings — to be presented in poster form on December 6, from 5:30 PM to 7:30 PM, in the West Building, Level 1 — may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma, the study authors say. The study focused on exosomes, tiny sacs that cells release into the bloodstream as a way of communicating with other cells. The exosomes contain microRNA molecules, fragments of RNA that help control the activity of genes…